{
  "investment_performance": [
    "Total Committed Capital: $43.02M",
    "Capital Called: $43.02M",
    "Distributions to Date: $0",
    "Net TVPI: 1.32x",
    "Net DPI: 0.00x",
    "Accrued Carry Fees: $2.88M",
    "Partners\u2019 Residual Capital Balance: $57.2M",
    "Net Q3 2025 Income: $4.58M, driven by unrealized gains of ~$4.8M",
    "Highest performing position:",
    "Precision Medication: $1.45M cost \u2192 $16.31M value (11.25x MOIC)",
    "Other notable positions:",
    "Benefitbay: $2.6M cost \u2192 $5.16M value (1.98x MOIC across tranches)",
    "Elife: $3.5M cost \u2192 $6.84M value (1.95x MOIC)",
    "Revi: $1.25M cost \u2192 $3.0M value (2.4x MOIC overall)",
    "Total unrealized gain: $22.1M on a $37.2M cost basis across portfolio"
  ],
  "key_takeaways": [
    "Portfolio saw two material Q3 markups (Precision Medication, Revi) and four markdowns (including Benefitbay and Stage Meta), with overall net unrealized gain of ~$4.8M in Q3.",
    "Benefitbay and HelloHero received follow-on investments in Q3.",
    "No cash distributions yet, but the portfolio has significant upside potential, especially from positions like Precision Medication and Benefitbay.",
    "Precision Medication rebounded sharply after halting GLP-1 compounding (formerly 70%+ of revenue). It is now EBITDA positive and has a clear runway to dominance in the D2C compounding space."
  ],
  "business_updates": [
    "Overall portfolio quality improving, with several companies nearing inflection points or successfully executing pivots.",
    "Liquidity events:",
    "Upswot sold to Uptiq; conversion into equity with ~25% of proceeds in holdback.",
    "Qeepsake executed an all-stock asset sale to Tinybeans; proceeds expected post 24-month lockup.",
    "Macro environment still poses challenges, but many portfolio companies are adapting by shifting to cash-flow positive operations or raising insider-led rounds at reasonable valuations.",
    "GPs remain actively involved, especially in distressed or pivoting companies, with hands-on support through capital raises, restructurings, and GTM strategies."
  ]
}